UU_logo.jpg
logo-uio-300.jpg
hi-logo_transparent-black-en.jpg

March 23, 2018

Association for Responsible Research and Innovation in Genome Editing hosts inaugural meeting in Paris

Biomodifying Technologies project team member Andy Bartlett was one of the attendees at the launch of a new international association dedicated to finding socially responsible ways of using gene editing technologies like CRISPR/cas9. The Association for Responsible Research and Innovation in Genome Editing (ARRIGE) states  its mission as being  "to promote a global governance of genome editing" and aims to provide a space where many different groups, including "academics, researchers, clinicians, public institutions, private companies, patient organizations and other NGOs, regulators, citizens, communication media, governmental agencies and decision makers" can meet and discuss what a mutually agreeable framework for translating gene editing into real world applications might look like.

More information about ARRIGE and information about members can be found via the link below.

January 11, 2018

New paper on regulating stem cell therapies in Low & Middle Income countries

A new paper co-authored by Jane Kaye and Michael Morrison from the Biomodifying Technologies project discusses the challenges of regulating stem cell science and translational research in smaller Low and Middle Income Countries (LMICs) using the example of Malaysia. Co-authored with Dr Mohammad Firdaus Bin Abdul Aziz of the University of Kuala Lumpur, the paper draws on interviews with scientists, and clinicians working on human stem cell research in Malaysia as well as with the regulators and ethicists  charged with regulating this emerging field to illustrate how the desire to advance Malaysia's competitive advantage in bringing new stem cell therapies to the clinic can be in tension with the need to protect the country's reputation as a legitimate and well-regulated member of the international scientific community.

October 10, 2017

Double special issue of Regenerative Medicine on interdisciplinary perspectives

The September and October issues of Regenerative Medicine comprise a double special focusing on social, legal and regulatory, ethical, and organisational aspects of innovation in cell and gene therapies. These thematic collections are guest edited by Achim Roseman (Warwick), Claire Blackburn and Jan Barfoot (both at the MRC Centre for Regenerative Medicine at the University of Edinburgh). The collection includes articles from several Biomodifying Technologies project members including Alex Faulkner, Andrew Webster, and Michael Morrison.

Some articles are open access and others require a subscription.

September 25, 2017

New paper on governance challenges for clinical gene editing

BioMod team member Michael Morrison is a co-author on a new paper reviewing “Key challenges in bringing CRISPR-mediated somatic cell therapy into the clinic”. The paper was published in the journal Genome Medicine and is the result of a symposium on genome editing hosted by the Centre for Law and Genetics at the University of Tasmania. The paper is open access and is available through the link below:

Please reload